When bad things happen to good studies

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3497-3499

  Manola, Judith B ^a   Gray, Robert J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

CANCER INCIDENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; DISEASE SURVEILLANCE; EDITORIAL; EFFECT SIZE; HEAD AND NECK CARCINOMA; HUMAN; MEDICARE; MORTALITY; OVERALL SURVIVAL; PATIENT INFORMATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT CANCER; RISK REDUCTION; SAMPLE SIZE;

CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; COMORBIDITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE;

EID: 80053043474     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.1393     Document Type: Editorial

References (22)

1. Rose BS, Jeong J-H, Nath SK, et al: Population-based study of competing mortality in head and neck cancer. J Clin Oncol 29:3503-3509, 2011
2. Quon H, Leong T, Haselow R, et al: Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys [Epub ahead of print on September 30, 2010]
3. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 21:327-333, 2003 (Pubitemid 46606163)
4. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
5. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999 (Pubitemid 30019568)
6. Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69-76, 2004 (Pubitemid 41095116)
7. Lefebvre JL, Rolland F, Tesselaar M, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142-152, 2009
8. Gibson MK, Li Y, Murphy B, et al: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562-3567, 2005
9. Hitt R, López-Pousa A, Martínez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005 (Pubitemid 46211506)
10. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
11. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
12. Janot F, De Raucourt D, Benhamou E, et al: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26:5518-5523, 2008
13. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005 (Pubitemid 46211507)
14. Vermorken JB, Remenar E, Van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007 (Pubitemid 350005151)
15. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
16. Lorch JH, Goloubeva O, Haddad RI, et al: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153-159, 2011
17. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
18. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
19. Machiels JP, Subramanian S, Ruzsa A, et al: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomized phase 3 trial. Lancet Oncol 12:333-343, 2011
20. Lachin JM, Foulkes MA: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507-519, 1986
21. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
22. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999